Published

Serotonergic psychedelics for depression: A comprehensive overview.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: International review of neurobiology
Date: 2025-01-01
Source: PubMed
DOI: 10.1016/bs.irn.2025.04.009
PubMed: 40541312

Authors

Wingert AM Agnorelli C Peill J Reed S Nutt DJ Erritzoe D

Watch author

Derived topics and classifications

psilocybin Depression Mechanism of Action Receptor Pharmacology Clinical Trial Review Article Treatment-Resistant Depression Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10 Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled TrialClinicalTrials.gov · 2026-05-07 Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.ClinicalTrials.gov · 2025-09-10 Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?UKnowledge (University of Kentucky) · 2025-03-04 Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelicsFrontiers in Psychiatry · 2024-11-06 Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?Clinical Pharmacology & Therapeutics · 2023-10-05 Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)ClinicalTrials.gov · 2026-07-30